Immune checkpoint inhibitors represented by anti-PD-1/PD-L1 and anti-CTLA-4 antibodies have shown good results in the clinical treatment of HCC, providing a new treatment method for HCC patients (Table 1). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.